Akcea Therapeutics Inc (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals Inc, has named Kia Motesharei, PhD as its new senior vice president of Business Development & Corporate Strategy, it was reported on Tuesday.
In the new role, Dr Motesharei is to manage business development activities at Akcea and will continue to improve the corporate strategy in collaboration with the Akcea leadership team.
Dr Motesharei has over 20 years of business and corporate development and strategy experience with multinational companies. Prior to joining Akcea Therapeutics, Dr Motesharei served Merck KGaA for six-years, where he most recently served as vice president and global head of Licensing and Business Development, Neurology & Immunology. He has also held the positions of vice president of Business Development & Alliance Management at Dyax Corp, chief business Officer at Genfit and vice president of Corporate Development at ActivX.
Biophytis secures Asian partnership and investment to advance Phase 3 sarcopenia programme
OncoHost receives BIG Innovation Award in Health category
MemorialCare hospitals recognised in 2026 Women's Choice Awards
Champions Oncology expands bioanalytical services with new technology and leadership
PhaseV receives three industry honours for AI in clinical development
Galapagos plans to wind down cell therapy business following strategic review
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Revelation Pharma acquires Acacia Apothecary & Wellness
Viatris receives fifth consecutive recognition on Forbes' annual list of World's Best Employers
INOVIO announces inducement grant to new employee
AbbVie's Allergan Aesthetics announces Natrelle supplier agreement with Vizient
Karyopharm Therapeutics awards inducement grants to new employees